Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471803 | 0.90 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL1794970 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL13603224 | 0.84 | LMNA (0.63) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL2932789 | 0.82 | MAPT (0.43) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL4463070 | 0.82 | PDE7A (0.44) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL12616280 | 0.82 | MAPT (0.66) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL2934318 | 0.81 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL4462548 | 0.81 | MAPT (0.48) | ALDH1A1LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL1794794 | 0.81 | LMNA (0.55) | ALDH1A1LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL18418113 | 0.80 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013207-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2012-04-25 | — | — | EP | disclosed |
| US-7951819-B2 | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7951819-B2 | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7951819-B2 | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2009-12-31 | — | — | US | disclosed |
| CN-101479264-A | Imidazo [4,5-B] pyridin-2-one and oxazolido [4,5-B] pyridin-2-one compounds and analogues thereof as compounds therapeutic for cancer | CANCER REC TECH LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| EP-2013207-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | Cancer Research Technology Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007125330-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125330-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | NR2E1, NR0B1, NR2E3 | ALDH1A1 2105/4885LMNA 1337/4885MAPT 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.